{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:14:03Z","timestamp":1779268443919,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CVIR Endovasc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate artery embolisation is an increasingly common, minimally invasive procedure performed for lower urinary tract symptoms caused by benign prostatic hyperplasia, with numerous systematic reviews and meta-analyses concluding that PAE is safe and effective. Despite mounting evidence supporting its role in treating BPH, variability and debate exist across various practical and technical factors associated with PAE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>PAE requires the use of a permanent embolic, typically microparticles or a liquid embolic, to induce ischaemia within the transitional zone of the prostate and shrink hyperplastic nodules. Microparticles have a large body of evidence that has established them as safe and effective. Liquid embolics can reduce procedure time and radiation dose but require operator experience with preparation and delivery. Pre-procedural CTA and cone beam CT are useful in defining anatomy and identifying non-target vasculature with the aim to reduce procedure time and risk of non-target embolisation but are associated with increased radiation dose. PAE can be safely performed from either a femoral or radial approach. Femoral access may be associated with higher rates of local complications and radial access is generally preferred by patients, although patient anatomy should be considered when selecting the site of access. There is recent evidence supporting the use of PAE as first-line therapy for BPH or as an adjunct prior to surgical intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prostate artery embolisation is an important treatment option within the algorithm for managing BPH, and has matured into a credible, evidence-based option alongside surgery and medications. While the efficacy and safety of PAE are well established, varied technical considerations exist regarding embolic choice, access route, imaging adjuncts and the procedure\u2019s role within the treatment sequence. Current data supports a pragmatic, anatomy-driven approach that prioritises procedural precision, embolic control, and patient-centred decision-making over adherence to a single technique.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42155-026-00689-5","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T01:48:09Z","timestamp":1776822489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current considerations in prostate artery embolisation"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1927-6160","authenticated-orcid":false,"given":"Peter","family":"Mark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas I.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E. L.","family":"Ormiston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"689_CR1","unstructured":"Demeritt JS, Elmasri FF, Esposito MP, Rosenberg GS. Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization 1. Report."},{"key":"689_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1106637","author":"AV Sarma","year":"2012","unstructured":"Sarma AV, Wei JT. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012. https:\/\/doi.org\/10.1056\/NEJMcp1106637.","journal-title":"N Engl J Med"},{"key":"689_CR3","doi-asserted-by":"publisher","unstructured":"Devlin CM, Simms MS, Maitland NJ, John Wiley and Sons Inc. Benign prostatic hyperplasia \u2013 what do we know? BJU Int. 2021(4). https:\/\/doi.org\/10.1111\/bju.15229.","DOI":"10.1111\/bju.15229"},{"issue":"5","key":"689_CR4","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1097\/01.ju.0000133655.71782.14","volume":"172","author":"K Lee","year":"2004","unstructured":"Lee K, Peehl D. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol. 2004;172(5):1784\u201391. https:\/\/doi.org\/10.1097\/01.ju.0000133655.71782.14.","journal-title":"J Urol"},{"key":"689_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00330-018-5564-2","volume":"29","author":"B Malling","year":"2019","unstructured":"Malling B, R\u00f8der MA, Brasso K, Forman J, Taudorf M, L\u00f6nn L. Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Radiol. 2019;29:287\u201398. https:\/\/doi.org\/10.1007\/s00330-018-5564-2.","journal-title":"Eur Radiol"},{"issue":"1","key":"689_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","volume":"64","author":"M Oelke","year":"2013","unstructured":"Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118\u201340. https:\/\/doi.org\/10.1016\/j.eururo.2013.03.004.","journal-title":"Eur Urol"},{"issue":"6","key":"689_CR7","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/j.1464-410X.2011.10124.x","volume":"107","author":"CG Roehrborn","year":"2011","unstructured":"Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind combination of Avodart and Tamsulosin (CombAT) trial. BJU Int. 2011;107(6):946\u201354. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10124.x.","journal-title":"BJU Int"},{"key":"689_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-020-00985-0","author":"R Dornbier","year":"2020","unstructured":"Dornbier R, Pahouja G, Branch J, McVary KT, Springer. The new American Urological Association benign prostatic hyperplasia clinical guidelines: 2019 update. Curr Urol Rep. 2020. https:\/\/doi.org\/10.1007\/s11934-020-00985-0.","journal-title":"Curr Urol Rep"},{"issue":"1","key":"689_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. 2024;211(1):11\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000003698.","journal-title":"J Urol"},{"key":"689_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-07663-2","author":"P Xiang","year":"2021","unstructured":"Xiang P, Guan D, Du Z, Hao Y, Yan W, Wang Y, et al. Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. Eur Radiol. 2021. https:\/\/doi.org\/10.1007\/s00330-020-07663-2.","journal-title":"Eur Radiol"},{"issue":"1","key":"689_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.juro.2008.03.058","volume":"180","author":"O Reich","year":"2008","unstructured":"Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246\u20139. https:\/\/doi.org\/10.1016\/j.juro.2008.03.058.","journal-title":"J Urol"},{"issue":"12","key":"689_CR12","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1007\/s00345-021-03779-2","volume":"39","author":"D Bouhadana","year":"2021","unstructured":"Bouhadana D, Nguyen DD, Zhang X, Mao J, Elterman DS, Te AE, et al. Safety and efficacy of TURP vs. laser prostatectomy for the treatment of benign prostatic hyperplasia in multi-morbid and elderly individuals aged \u2265 75. World J Urol. 2021;39(12):4405\u201312. https:\/\/doi.org\/10.1007\/s00345-021-03779-2.","journal-title":"World J Urol"},{"key":"689_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-021-03052-4","author":"T Bilhim","year":"2022","unstructured":"Bilhim T, Betschart P, Lyatoshinsky P, M\u00fcllhaupt G, Abt D. Minimally invasive therapies for benign prostatic obstruction: a review of currently available techniques including prostatic artery embolization, water vapor thermal therapy, prostatic urethral lift, temporary implantable nitinol device and aquablation. Cardiovasc Intervent Radiol. 2022. https:\/\/doi.org\/10.1007\/s00270-021-03052-4.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"689_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jvir.2023.09.036","volume":"35","author":"AJ Richardson","year":"2024","unstructured":"Richardson AJ, Kumar J, Richardson K, Bhatia A, Pennix T, Shah K, et al. Safety of prostatic artery embolization via transradial access versus transfemoral access. J Vasc Interv Radiol. 2024;35(4):541\u20137. https:\/\/doi.org\/10.1016\/j.jvir.2023.09.036.","journal-title":"J Vasc Interv Radiol"},{"key":"689_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.09.005","author":"V Zumstein","year":"2019","unstructured":"Zumstein V, Betschart P, Vetterlein MW, Kluth LA, Hechelhammer L, Mordasini L, et al. Prostatic artery embolization versus standard surgical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol Focus. 2019. https:\/\/doi.org\/10.1016\/j.euf.2018.09.005.","journal-title":"Eur Urol Focus"},{"key":"689_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2021.779571","author":"Z Xu","year":"2021","unstructured":"Xu Z, Zhou Z, Mu Y, Cai T, Gao Z, Liu L. An updated meta-analysis of the efficacy and safety of prostatic artery embolization vs. transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. Front Surg. 2021. https:\/\/doi.org\/10.3389\/fsurg.2021.779571.","journal-title":"Front Surg"},{"issue":"1","key":"689_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jvir.2013.09.010","volume":"25","author":"S Bagla","year":"2014","unstructured":"Bagla S, Martin CP, Van Breda A, Sheridan MJ, Sterling KM, Papadouris D, et al. Early results from a united states trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2014;25(1):47\u201352. https:\/\/doi.org\/10.1016\/j.jvir.2013.09.010.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"689_CR18","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s00270-022-03069-3","volume":"45","author":"E Salet","year":"2022","unstructured":"Salet E, Cromb\u00e9 A, Grenier N, Marcelin C, Lebras Y, Jambon E, et al. Prostatic artery embolization for benign prostatic obstruction: single-centre retrospective study comparing microspheres versus n-butyl cyanoacrylate. Cardiovasc Intervent Radiol. 2022;45(6):814\u201323. https:\/\/doi.org\/10.1007\/s00270-022-03069-3.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"9","key":"689_CR19","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00330-012-2714-9","volume":"23","author":"JM Pisco","year":"2013","unstructured":"Pisco JM, Rio Tinto H, Campos Pinheiro L, Bilhim T, Duarte M, Fernandes L, et al. Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up. Eur Radiol. 2013;23(9):2561\u201372. https:\/\/doi.org\/10.1007\/s00330-012-2714-9.","journal-title":"Eur Radiol"},{"issue":"5","key":"689_CR20","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.jvir.2019.02.014","volume":"30","author":"D Torres","year":"2019","unstructured":"Torres D, Costa NV, Pisco J, Pinheiro LC, Oliveira AG, Bilhim T. Prostatic artery embolization for benign prostatic hyperplasia: prospective randomized trial of 100\u2013300 \u03bcm versus 300\u2013500 \u03bcm versus 100- to 300-\u03bcm + 300- to 500-\u03bcm embospheres. J Vasc Interv Radiol. 2019;30(5):638\u201344. https:\/\/doi.org\/10.1016\/j.jvir.2019.02.014.","journal-title":"J Vasc Interv Radiol"},{"issue":"12","key":"689_CR21","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.jvir.2018.06.019","volume":"29","author":"MQ Wang","year":"2018","unstructured":"Wang MQ, Zhang JL, Xin HN, Yuan K, Yan J, Wang Y, et al. Comparison of clinical outcomes of prostatic artery embolization with 50-\u03bcm plus 100-\u03bcm polyvinyl alcohol (PVA) particles versus 100-\u03bcm PVA particles alone: a prospective randomized trial. J Vasc Interv Radiol. 2018;29(12):1694\u2013702. https:\/\/doi.org\/10.1016\/j.jvir.2018.06.019.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"689_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.crad.2019.12.019","volume":"75","author":"R Geevarghese","year":"2020","unstructured":"Geevarghese R, Harding J, Parsons N, Hutchinson C, Parsons C. The relationship of embolic particle size to patient outcomes in prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-regression. Clin Radiol. 2020;75(5):366\u201374. https:\/\/doi.org\/10.1016\/j.crad.2019.12.019.","journal-title":"Clin Radiol"},{"issue":"6","key":"689_CR23","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1007\/s00270-014-0908-z","volume":"37","author":"FC Carnevale","year":"2014","unstructured":"Carnevale FC, Moreira AM, Antunes AA. The \u201cPErFecTED technique\u201d: proximal embolization first, then embolize distal for benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2014;37(6):1602\u20135. https:\/\/doi.org\/10.1007\/s00270-014-0908-z.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"689_CR24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s00270-019-02379-3","volume":"43","author":"FH Cornelis","year":"2020","unstructured":"Cornelis FH, Bilhim T, Hacking N, Sapoval M, Tapping CR, Carnevale FC. Cirse standards of practice on prostatic artery embolisation. Cardiovasc Intervent Radiol. 2020;43(2):176\u201385. https:\/\/doi.org\/10.1007\/s00270-019-02379-3.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"689_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.diii.2023.12.006","volume":"105","author":"R Loffroy","year":"2024","unstructured":"Loffroy R, Quirantes A, Guillen K, Mazit A, Comby PO, Aho-Gl\u00e9l\u00e9 LS, et al. Prostate artery embolization using n-butyl cyanoacrylate glue for symptomatic benign prostatic hyperplasia: a six-month outcome analysis in 103 patients. Diagn Interv Imaging. 2024;105(4):129\u201336. https:\/\/doi.org\/10.1016\/j.diii.2023.12.006.","journal-title":"Diagn Interv Imaging"},{"issue":"9","key":"689_CR26","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00270-025-04164-x","volume":"48","author":"J S\u00e9dat","year":"2025","unstructured":"S\u00e9dat J, Fontas E, Arnoffi P, Stranieri G, Colomb F, Chau Y. Prostatic artery embolization using ethylene vinyl alcohol (EVOH) copolymer for benign prostatic hyperplasia: twelve-month analysis. Cardiovasc Intervent Radiol. 2025;48(9):1369\u201375. https:\/\/doi.org\/10.1007\/s00270-025-04164-x.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"689_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s42155-021-00249-z","volume":"4","author":"FC Carnevale","year":"2021","unstructured":"Carnevale FC, McClure T, Cadour F, Vidal V, de Assis AM, Moreira AM, et al. Advanced image guidance for prostatic artery embolization \u2013 a multicenter technical note. CVIR Endovasc. 2021;4(1):63. https:\/\/doi.org\/10.1186\/s42155-021-00249-z.","journal-title":"CVIR Endovasc"},{"issue":"1","key":"689_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s42155-024-00459-1","volume":"7","author":"N Rostambeigi","year":"2024","unstructured":"Rostambeigi N, Crawford D, Golzarian J. Benefits and advances of cone beam CT use in prostatic artery embolization: review of the literature and pictorial essay. CVIR Endovasc. 2024;7(1):46. https:\/\/doi.org\/10.1186\/s42155-024-00459-1.","journal-title":"CVIR Endovasc"},{"issue":"10","key":"689_CR29","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s00270-017-1765-3","volume":"40","author":"AM Moreira","year":"2017","unstructured":"Moreira AM, de Assis AM, Carnevale FC, Antunes AA, Srougi M, Cerri GG. A review of adverse events related to prostatic artery embolization for treatment of bladder outlet obstruction due to BPH. Cardiovasc Intervent Radiol. 2017;40(10):1490\u2013500. https:\/\/doi.org\/10.1007\/s00270-017-1765-3.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"689_CR30","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00270-017-1842-7","volume":"41","author":"D Maclean","year":"2018","unstructured":"Maclean D, Maher B, Harris M, Dyer J, Modi S, Hacking N, et al. Planning prostate artery embolisation: is it essential to perform a pre-procedural CTA? Cardiovasc Intervent Radiol. 2018;41(4):628\u201332. https:\/\/doi.org\/10.1007\/s00270-017-1842-7.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"11","key":"689_CR31","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.jvir.2013.06.024","volume":"24","author":"S Bagla","year":"2013","unstructured":"Bagla S, Rholl KS, Sterling KM, van Breda A, Papadouris D, Cooper JM. Utility of cone-beam CT imaging in prostatic artery embolization. J Vasc Interv Radiol. 2013;24(11):1603\u20137. https:\/\/doi.org\/10.1016\/j.jvir.2013.06.024.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"689_CR32","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2021.0934","volume":"23","author":"R Gil","year":"2022","unstructured":"Gil R, Shim DJ, Kim D, Lee DH, Kim JJ, Lee JW. Prostatic artery embolization for lower urinary tract symptoms via transradial versus transfemoral artery access: single-center technical outcomes. Korean J Radiol. 2022;23(5):548. https:\/\/doi.org\/10.3348\/kjr.2021.0934.","journal-title":"Korean J Radiol"},{"issue":"2","key":"689_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/j.tvir.2015.04.002","volume":"18","author":"AM Fischman","year":"2015","unstructured":"Fischman AM, Swinburne NC, Patel RS. A technical guide describing the use of transradial access technique for endovascular interventions. Tech Vasc Interv Radiol. 2015;18(2):58\u201365. https:\/\/doi.org\/10.1053\/j.tvir.2015.04.002.","journal-title":"Tech Vasc Interv Radiol"},{"key":"689_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.carrev.2021.12.007","volume":"40","author":"S Roy","year":"2022","unstructured":"Roy S, Kabach M, Patel DB, Guzman LA, Jovin IS. Radial artery access complications: prevention, diagnosis and management. Cardiovasc Revasc Med. 2022;40:163\u201371. https:\/\/doi.org\/10.1016\/j.carrev.2021.12.007.","journal-title":"Cardiovasc Revasc Med"},{"issue":"1","key":"689_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ccd.25884","volume":"86","author":"L Raposo","year":"2015","unstructured":"Raposo L, Madeira S, Teles RC, Santos M, Gabriel HM, Gon\u00e7alves P, et al. Neurologic complications after transradial or transfemoral approach for diagnostic and interventional cardiac catheterization: a propensity score analysis of 16,710 cases from a single centre prospective registry. Catheter Cardiovasc Interv. 2015;86(1):61\u201370. https:\/\/doi.org\/10.1002\/ccd.25884.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"11","key":"689_CR36","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/j.jvir.2025.05.033","volume":"36","author":"Y Koretsune","year":"2025","unstructured":"Koretsune Y, Sone M, Kimura S, Sugawara S, Kodama Y, Kimura Y, et al. Prospective multicenter observational study of silent brain infarction following transradial hepatic intervention (The MOSAIC Study). J Vasc Interv Radiol. 2025;36(11):1648-1657.e1. https:\/\/doi.org\/10.1016\/j.jvir.2025.05.033.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"689_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13010087","volume":"13","author":"B Moulin","year":"2022","unstructured":"Moulin B, Di Primio M, Vignaux O, Sarrazin JL, Angelopoulos G, Hakime A. Prostate artery embolization: challenges, tips, tricks, and perspectives. J Pers Med. 2022;13(1):87. https:\/\/doi.org\/10.3390\/jpm13010087.","journal-title":"J Pers Med"},{"key":"689_CR38","unstructured":"Therapeutic Goods Administration. Australian Public Assessment Report for Dutasteride\/Tamsulosin About the Therapeutic Goods Administration (TGA). 2011. Report. Available from: http:\/\/www.ag.gov.au\/cca."},{"issue":"S2","key":"689_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/bju.16479","volume":"134","author":"N Brown","year":"2024","unstructured":"Brown N, Kiosoglous A, Castree S, Firouzmand S, McBean R, Walker DG, et al. The \u201cProstate Embolisation AS first-line therapY compAred to meDication in treatment na\u00efVe men with prostAte eNlargement, a randomised ControllEd trial\u201d (P-EASY ADVANCE): a randomised controlled trial of prostate embolisation vs medication for BPH. BJU Int. 2024;134(S2):38\u201346. https:\/\/doi.org\/10.1111\/bju.16479.","journal-title":"BJU Int"},{"key":"689_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100672","volume":"31","author":"M Sapoval","year":"2023","unstructured":"Sapoval M, Thiounn N, Descazeaud A, D\u00e9an C, Ruffion A, Pagnoux G, et al. Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial. The Lancet Regional Health - Europe. 2023;31:100672. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100672.","journal-title":"The Lancet Regional Health - Europe"},{"key":"689_CR41","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.231877","author":"R Ayyagari","year":"2024","unstructured":"Ayyagari R, Rahman SZ, Grizzard K, Mustafa A, Staib LH, Makkia RS, et al. Multicenter quantification of radiation exposure and associated risks for prostatic artery embolization in 1476 patients. Radiology. 2024. https:\/\/doi.org\/10.1148\/radiol.231877.","journal-title":"Radiology"},{"issue":"3","key":"689_CR42","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.euf.2020.04.012","volume":"7","author":"V Zumstein","year":"2021","unstructured":"Zumstein V, Binder J, G\u00fcsewell S, Betschart P, Pratsinis M, M\u00fcllhaupt G, et al. Radiation exposure during prostatic artery embolisation: a systematic review and calculation of associated risks. Eur Urol Focus. 2021;7(3):608\u201311. https:\/\/doi.org\/10.1016\/j.euf.2020.04.012.","journal-title":"Eur Urol Focus"},{"issue":"2 Part 2","key":"689_CR43","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0022-5347(02)80323-8","volume":"167","author":"WK Mebust","year":"2002","unstructured":"Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC, Writing Committee. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol. 2002;167(2 Part 2):999\u20131003. https:\/\/doi.org\/10.1016\/S0022-5347(02)80323-8.","journal-title":"J Urol"},{"issue":"1","key":"689_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.prnil.2024.10.004","volume":"13","author":"AYM Lee","year":"2025","unstructured":"Lee AYM, Neo SH, Brodie BA, Ng TK, Aslim EJ, Chin ZY, et al. Preoperative prostatic artery embolization before transurethral resection of the prostate for prostate glands larger than 80\u00a0mL: the first randomized controlled trial. Prostate Int. 2025;13(1):22\u20137. https:\/\/doi.org\/10.1016\/j.prnil.2024.10.004.","journal-title":"Prostate Int"},{"issue":"11","key":"689_CR45","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1007\/s00345-021-03747-w","volume":"39","author":"M Parmar","year":"2021","unstructured":"Parmar M, Katz JE, Blachman-Braun R, Smith NA, Oneto SM, Bhatia S, et al. Safety and efficacy of holmium laser enucleation of prostate as salvage procedure for persistent or recurrent lower urinary tract symptoms secondary to bladder outlet obstruction after prior prostate artery embolization: a match analysis. World J Urol. 2021;39(11):4199\u2013206. https:\/\/doi.org\/10.1007\/s00345-021-03747-w.","journal-title":"World J Urol"},{"issue":"4","key":"689_CR46","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1159\/000478788","volume":"99","author":"P Li","year":"2017","unstructured":"Li P, Wang C, Cao Q, Zhang J, Shi H, Meng X. Prostatic arterial embolization followed by holmium laser enucleation of the prostate as a planned combined approach for extremely enlarged benign prostate hyperplasia. Urol Int. 2017;99(4):422\u20138. https:\/\/doi.org\/10.1159\/000478788.","journal-title":"Urol Int"},{"issue":"3","key":"689_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.11.004","volume":"6","author":"J Peacock","year":"2021","unstructured":"Peacock J, Sikaria D, Maun-Garcia L, Javedan K, Yamoah K, Parikh N. A proof-of-concept study on the use of prostate artery embolization before definitive radiation therapy in prostate cancer. Adv Radiat Oncol. 2021;6(3):100619. https:\/\/doi.org\/10.1016\/j.adro.2020.11.004.","journal-title":"Adv Radiat Oncol"},{"key":"689_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2025.101035","volume":"55","author":"VM Khatri","year":"2025","unstructured":"Khatri VM, Grass GD, Thapa R, Maun-Garcia L, Latifi K, Naghavi AO, et al. Neoadjuvant prostate artery embolization prior to prostate radiation therapy: a single institution experience on the durability of clinical urinary improvement after radiation. Clin Transl Radiat Oncol. 2025;55:101035. https:\/\/doi.org\/10.1016\/j.ctro.2025.101035.","journal-title":"Clin Transl Radiat Oncol"},{"key":"689_CR49","doi-asserted-by":"publisher","DOI":"10.1177\/10732748251317691","author":"N Parikh","year":"2025","unstructured":"Parikh N, Yamoah K, Johnstone P, Torres-Roca J, Pow-Sang J, Fernandez D, et al. Prostate artery embolization in the setting of prostate cancer: review and opinion. Cancer Control. 2025. https:\/\/doi.org\/10.1177\/10732748251317691.","journal-title":"Cancer Control"},{"issue":"1","key":"689_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s42155-024-00464-4","volume":"7","author":"R Wise","year":"2024","unstructured":"Wise R, Fu H, Tapping CR. Prostate volume: does it predict patient outcomes following prostate artery embolisation? A retrospective cohort study. CVIR Endovasc. 2024;7(1):51. https:\/\/doi.org\/10.1186\/s42155-024-00464-4.","journal-title":"CVIR Endovasc"},{"issue":"8","key":"689_CR51","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1007\/s00270-018-1912-5","volume":"41","author":"D Maclean","year":"2018","unstructured":"Maclean D, Harris M, Drake T, Maher B, Modi S, Dyer J, et al. Factors predicting a good symptomatic outcome after prostate artery embolisation (PAE). Cardiovasc Intervent Radiol. 2018;41(8):1152\u20139. https:\/\/doi.org\/10.1007\/s00270-018-1912-5.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"689_CR52","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.21037\/tau-20-437","volume":"9","author":"F Sun","year":"2020","unstructured":"Sun F, Lucas-Cava V, S\u00e1nchez-Margallo FM. Clinical predictive factors in prostatic artery embolization for symptomatic benign prostatic hyperplasia: a comprehensive review. Transl Androl Urol. 2020;9(4):1754\u201368. https:\/\/doi.org\/10.21037\/tau-20-437.","journal-title":"Transl Androl Urol"},{"issue":"5","key":"689_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10050304","volume":"10","author":"B Malling","year":"2020","unstructured":"Malling B, R\u00f8der MA, Lauridsen C, L\u00f6nn L. Can computed tomography perfusion predict treatment response after prostate artery embolization: a feasibility study. Diagnostics. 2020;10(5):304. https:\/\/doi.org\/10.3390\/diagnostics10050304.","journal-title":"Diagnostics"},{"issue":"15","key":"689_CR54","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.7314\/APJCP.2014.15.15.6375","volume":"15","author":"S Tanik","year":"2014","unstructured":"Tanik S, Albayrak S, Zengin K, Borekci H, Bakirtas H, Imamoglu MA, et al. Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? Asian Pac J Cancer Prev. 2014;15(15):6375\u20139. https:\/\/doi.org\/10.7314\/APJCP.2014.15.15.6375.","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["CVIR Endovascular"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42155-026-00689-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42155-026-00689-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42155-026-00689-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T01:48:15Z","timestamp":1776822495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42155-026-00689-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["689"],"URL":"https:\/\/doi.org\/10.1186\/s42155-026-00689-5","relation":{},"ISSN":["2520-8934"],"issn-type":[{"value":"2520-8934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval from patients with regard to sharing of de-identified images has been obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}